Latest news with #JEB
Hamilton Spectator
30-07-2025
- Business
- Hamilton Spectator
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, July 30, 2025 Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed a non-binding term sheet with Evotec SE. This paves the way for Sandoz to potentially acquire 100% of the issued and outstanding equity interests of Just–Evotec Biologics EU SAS for an amount of around USD 300 million, which owns the biologics development and manufacturing facility in Toulouse, France. Richard Saynor, CEO of Sandoz, said: 'We aim to capitalize on the projected USD 300 billion biosimilar market opportunity over the next decade. The intended acquisition is fully in line with our strategy to reinforce in-house biosimilar capabilities, while creating additional strategic flexibility. Following successful completion, the Toulouse site would be used to develop and manufacture Sandoz biosimilars. JEB´s fully automated and high throughput technology platform will help us move faster, scale smarter, and maintain high quality while keeping costs under control.' Sandoz and Evotec SE will now work to negotiate details of the contracts and carry out the relevant works-council consultation processes, as well as the mandatory employee bid process in France. Closing the proposed transaction will be subject to finalizing the contracts and obtaining all necessary approvals. Further details of the terms cannot be shared at this stage and will only be disclosed after successful signing of the contracts. Just-Evotec Biologics has been a key strategic partner for Sandoz since 2023. The proposed acquisition would complement previously announced investments in Sandoz biosimilar manufacturing and development sites. The planned investment would be in line with existing Sandoz capital-expenditure commitments related to Sandoz operations in Europe. Upon completion of the proposed transaction, JEB employees would transfer with the acquired entity and would become part of the Sandoz Group. JEB brings an advanced and integrated continuous manufacturing platform with automation that enables manufacturing to run continuously end-to-end. About Sandoz agreement with JEB In May 2023, Sandoz and JEB announced a strategic partnership that supports the company's portfolio expansion and continued development of its early-stage biosimilar pipeline by providing access to JEB's highly-efficient drug substance development platform. The proprietary fully automated and high throughput technology platform allows Sandoz to continue to build out its own integrated drug substance development and manufacturing network. JEB is also developing an integrated continuous manufacturing platform with automation that enables the manufacturing process to run continuously end-to-end, resulting in enhanced efficiency and cost-effectiveness. In July 2024, Sandoz secured long-term commercial supply access to JEB's biosimilars manufacturing facility in Toulouse, France. In addition, Sandoz secured resource capacity for drug substance development of additional molecules starting in 2025. JEB will also enable the implementation of its design capability and continuous manufacturing technology at Sandoz. DISCLAIMER This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law. ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world's first oral penicillin in 1951, and the world's first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. Attachment
Yahoo
20-04-2025
- Entertainment
- Yahoo
Hannah Campbell Shares Heartbreaking Message Amid Baby Girl's Funeral
Originally appeared on E! Online Hannah Campbell is in mourning. The TikToker made her first social media post since sharing news of 10-month-old daughter Elliana's death, posting a video of herself, husband Jacob Campbell and their older daughter Ember getting ready for the funeral. Set to Andra Day's song "Rise Up," the clip showed Hannah solemnly putting on makeup, before donning a gold necklace and beaded bracelet adorned with a charm baring her late baby girl's initial. "Today we dress with heavy hearts to celebrate a life that changed ours forever," Hannah wrote on TikTok April 12. "This is for you, Ellie." Elliana passed away on April 7, less than one year after she was diagnosed with junctional epidermolysis bullosa (JEB). 'Our sweet girl Elliana Rose lost her battle last night," Hannah captioned an April 8 TikTok. "She passed peacefully, wrapped in love." JEB is a rare condition that causes fragile and blistering skin, according to Mayo Clinic. The genetic disorder, which is largely found in infants, has no cure but can be improved with age. More from E! Online Sean Lowe Shares Health Update After Attack by Family Dog Khloe Kardashian Reveals Who Gets Paid the Most for The Kardashians Liv Tyler Details "Shock" of Discovering Steven Tyler Was Her Dad at Age 11 Hannah started documenting Elliana's JEB journey shortly after she was diagnosed with the condition at 2 weeks old. "Thought I was bringing a healthy baby girl into this world, little did I know what was to come," the content creator wrote on TikTok in October. "We are given an estimated time frame of around 9 months with our girl." She added at the time, "I am hesitant to post this, but if it helps spread awareness for this horrible disease then i want that for my baby. Every single day she is in pain, yet still manages to smile through it. She is so strong and so loved." In an April 14 TikTok posted on Hannah's account, Elliana's dermatologist said the baby girl suffered from a "severe" case of the condition. "Ellie was fighting for her life since the day she was born," the doctor shared. "There's nothing Ellie's parents could have done to change what happened. The encouraging news is that I do think there's hope on the horizon as science and gene therapy advances. We're not there yet, but in the years to come, I think we can get there." For the latest breaking news updates, click here to download the E! News App
Miami Herald
09-04-2025
- Health
- Miami Herald
TikToker Hannah Campbell loses 10-month-old daughter to rare skin disorder
A TikTok influencer is urging her followers to fight for a cure after losing her 10-month-old daughter to a terminal illness. On April 8, Hannah Campbell — who gave birth to Elliana Rose in May 2024 — shared a TikTok video in memory of her daughter, who died the night before. 'Our sweet girl Elliana Rose lost her battle last night. She passed peacefully, wrapped in love,' Campbell wrote in the video's caption. 'I don't know what to do with myself today. I'm heartbroken, and I'm angry.' Elliana Rose was diagnosed with a rare and highly severe condition called Junctional Epidermolysis Bullosa (JEB) at 2 weeks old. Campbell has documented her daughter's battle on TikTok since September to help raise awareness for the disease. 'No child should have to endure what she did. EB stole her from us. Let's fight for a cure so no other family has to feel this. Thank you for loving her with us,' Campbell added in the caption. According to DermNet, epidermolysis bullosa (EB) is 'a group of inherited diseases that are characterised by blistering lesions on the skin and mucous membranes.' The painful blisters can appear anywhere on the body and form from the slightest touch. It affects both the external and internal well-being of the individual. 'An estimated 1 in 50,000 people in the United States' have EB, according to Cleveland Clinic. While there is currently no cure for the disease, some patients can see their condition improve with age. In a March TikTok video explaining her daughter's condition, Campbell wrote that the disease 'causes daily pain, wounds and lifelong challenges.' She noted that her daughter requires 'constant wound care, special medical supplies and adaptive equipment to keep her comfortable and safe,' per E! News. 'There is no cure, but there is hope,' Campbell added. 'Every child with EB deserves a future without pain. Spreading awareness leads to research, treatments and one day a cure.' Campbell's latest update came just a few days after posting a video explaining that her daughter 'hasn't opened her beautiful eyes in 24 hours.' In the caption, Campbell added that Elliana was 'still with us, but her body is tired.' 'She hasn't opened her eyes, eaten, and can hardly cry. We're holding her close and loving her through every breath,' she wrote. In addition to using her TikTok to spread awareness to her more than 700,000 followers, Campbell founded Elliana's Hope for Healing — a fundraiser that hopes to find a cure for EB by 2030. On its official website, Campbell wrote that it was 'unlikely Elliana will live beyond her first year.' 'This fundraiser is being organized with the aim of providing support to Elliana and other babies facing similar health conditions,' Campbell wrote on the website. Campbell created the fundraiser with EB Research Partnership (EBRP), which was co-founded in 2010 by Jill and Eddie Vedder — the frontman for Pearl Jam — after their friend's son was diagnosed with EB. According to EBRP, Elliana was one of more than 400 million children and adults battling EB. 'Over the last decade, EBRP has made remarkable strides, including helping to accelerate the first two EB treatments FDA approved in 2023,' the nonprofit wrote on its website.
